Hengrui Medicine (01276.HK): HRS-4139 Tablets Receive Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Hengrui Pharmaceuticals (01276.HK) announced that recently, Fujian Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company"), received the Drug Clinical Trial Approval Notice for HRS-4139 tablets approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and will soon initiate clinical trials.